Cullinan Oncology, Inc.: directors' dealings · United States · SEC (Form 4)

About Cullinan Oncology, Inc.

Cullinan Oncology, Inc., now operating as Cullinan Therapeutics, Inc., is a US-based clinical-stage biopharmaceutical company listed on the NASDAQ under ticker CGEM. Headquartered in Cambridge, Massachusetts, United States, the company was incorporated in September 2016 and has built its strategy around a focused pipeline of high-conviction drug candidates rather than a broad commercial portfolio. For French-speaking investors, the investment case is that of a research-driven biotech: no approved products, no meaningful product-sales base, and valuation primarily tied to clinical readouts, regulatory milestones, and partnership execution. Originally centered on oncology, the company expanded its corporate identity in 2024 to better reflect a broader ambition that now also includes autoimmune disease. Cullinan’s current portfolio is led by CLN-978, a CD19xCD3 bispecific T-cell engager being developed for autoimmune disorders; CLN-049, a FLT3xCD3 T-cell engager focused on hematology/oncology, including AML and related settings; and zipalertinib, a targeted EGFR exon 20 insertion NSCLC therapy being co-developed with Taiho Pharmaceutical. The company’s model is typical of a late-preclinical/clinical biotech: advance only those programs that clear a high scientific bar, discontinue weaker assets early, and preserve capital for the most promising candidates. In competitive terms, Cullinan sits in one of the most challenging parts of the life sciences market. It competes with larger biopharma groups and specialist biotech peers in immunology, hematology, and precision oncology, where differentiation depends on mechanism of action, tolerability, biomarker strategy, and the ability to generate clean data quickly. The company’s geographic footprint is largely US-based from an operational standpoint, with a principal office in Cambridge, while its clinical and partnership activity may extend internationally depending on the program. Recent company news has been central to the story. During 2025 and into 2026, management highlighted multiple catalysts for CLN-978 and CLN-049, including ongoing data generation in autoimmune disease and AML programs. On the partnering side, Taiho advanced the regulatory path for zipalertinib, and FDA acceptance of the NDA increased visibility for that asset. At the same time, Cullinan demonstrated portfolio discipline by discontinuing CLN-617 after reviewing emerging clinical data. Overall, CGEM is best viewed as a US-listed NASDAQ biotech with a science-led, catalyst-heavy profile: potentially high upside if key programs succeed, but with the usual clinical-stage risks that come with dependency on data, timelines, and regulatory outcomes.